1. Home
  2. MRK
  3. MRK News

Latest Merck & Company Inc. (new) (MRK) News on October 25, 2025

Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch
MRK

Yahoo Finance Video

18 hours ago

Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch

Merck's Non-Oncology Drugs Q3 Performance: What to Expect
MRK

Zacks

a day ago

Merck's Non-Oncology Drugs Q3 Performance: What to Expect

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
MRK

Zacks

a day ago

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

United States Lipid Nanoparticle Market Forecast and Competitive Analysis Report 2025-2033 Featuring Merck, Evonik, Genevant Sciences, CordenPharma, Arcturus, Ascendia, Acuitas, Croda
MRK

GlobeNewswire

a day ago

United States Lipid Nanoparticle Market Forecast and Competitive Analysis Report 2025-2033 Featuring Merck, Evonik, Genevant Sciences, CordenPharma, Arcturus, Ascendia, Acuitas, Croda

eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
MRK

PR Newswire

2 days ago

eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience

Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
MRK

Zacks

2 days ago

Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Trump's Next Shock Move: U.S. Weighs Software Ban That Could Hit China's Tech Core
MRK

GuruFocus.com

2 days ago

Trump's Next Shock Move: U.S. Weighs Software Ban That Could Hit China's Tech Core

MRK

Business Wire

2 days ago

Net Asset Value(s)

MRK

MT Newswires

2 days ago

NioCorp, Lockheed Martin Collaborate on Scandium-Based Defense Technology

MRK

MT Newswires

2 days ago

BofA Securities Adjusts Price Target on NVR to $9,200 From $9,000, Maintains Buy Rating

MRK

MT Newswires

2 days ago

BofA Securities Adjusts Bumble Price Target to $5 From $5.50, Maintains Underperform Rating

MRK

MT Newswires

2 days ago

BofA Ups Price Target on International Business Machines to $315 From $310, Reports Solid 3Q; Maintains Buy Rating

MRK

MT Newswires

2 days ago

BofA Securities Adjusts Duolingo Price Target to $370 From $450, Maintains Neutral Rating

MRK

MT Newswires

2 days ago

BofA Raises Price Target on AeroVironment to $450 From $300 on Strong Product Demos, Maintains Buy Rating

Jim Cramer Says “Danaher Gave Us the Quarter We’ve Been Looking For”
MRK

Insider Monkey

2 days ago

Jim Cramer Says “Danaher Gave Us the Quarter We’ve Been Looking For”

MRK

MT Newswires

2 days ago

Merck Says FDA Granted Priority Review on Keytruda, Keytruda Qlex Applications for Bladder Cancer

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
MRK

Business Wire

2 days ago

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
MRK

Business Wire

2 days ago

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

Merck (MRK): Valuation Perspective as Groundbreaking Cancer Trial Wins Drive New Investor Focus
MRK

Simply Wall St.

3 days ago

Merck (MRK): Valuation Perspective as Groundbreaking Cancer Trial Wins Drive New Investor Focus

United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt
MRK

GlobeNewswire

4 days ago

United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt

MSD initiates construction on $3bn Virginia drug manufacturing site
MRK

Pharmaceutical Technology

4 days ago

MSD initiates construction on $3bn Virginia drug manufacturing site

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
MRK

GlobeNewswire

4 days ago

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
MRK

Business Wire

4 days ago

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
MRK

GlobeNewswire

4 days ago

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Merck (MRK) Outpaces Stock Market Gains: What You Should Know
MRK

Zacks

5 days ago

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

MRK

MT Newswires

5 days ago

Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint

MRK

MT Newswires

5 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
MRK

ACCESS Newswire

5 days ago

Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
MRK

GlobeNewswire

5 days ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
MRK

Business Wire

6 days ago

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
MRK

Business Wire

7 days ago

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
MRK

Investor's Business Daily

7 days ago

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
MRK

Business Wire

7 days ago

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
MRK

Business Wire

7 days ago

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
MRK

Zacks

8 days ago

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?

Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating
MRK

Insider Monkey

8 days ago

Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating

Trump Strikes Deal With Merck KGaA on Tariffs, IVF Costs
MRK

Bloomberg

8 days ago

Trump Strikes Deal With Merck KGaA on Tariffs, IVF Costs

EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
MRK

Business Wire

9 days ago

EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies

2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off
MRK

StockStory

9 days ago

2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
MRK

Zacks

9 days ago

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

MRK

MT Newswires

9 days ago

Merck Says Keytruda With Chemotherapy Phase 3 Ovarian Cancer Trial Meets Secondary Endpoint

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
MRK

Business Wire

9 days ago

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength
MRK

Insider Monkey

9 days ago

Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength

Germany’s Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets
MRK

The Wall Street Journal

9 days ago

Germany’s Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets

1 Profitable Stock Worth Your Attention and 2 Facing Challenges
MRK

StockStory

10 days ago

1 Profitable Stock Worth Your Attention and 2 Facing Challenges

Why Moderna Might Be a One-Hit Wonder
MRK

Motley Fool

10 days ago

Why Moderna Might Be a One-Hit Wonder

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations
MRK

GlobeNewswire

10 days ago

Non-Small Cell Lung Cancer Analysis Report 2025: Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and Strategic Pipeline Collaborations

MRK

MT Newswires

10 days ago

Merck Says Data From Late-Stage Studies Show Investigational Two-Drug HiV Therapy Maintains Viral Suppression

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships
MRK

GlobeNewswire

10 days ago

Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
MRK

Business Wire

10 days ago

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck (MRK) Declines More Than Market: Some Information for Investors
MRK

Zacks

11 days ago

Merck (MRK) Declines More Than Market: Some Information for Investors

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
MRK

Zacks

11 days ago

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
MRK

Motley Fool

11 days ago

Can $10,000 in Merck Stock Turn Into $50,000 by 2030?

Merck & Co. Earnings Preview: What to Expect
MRK

Barchart

11 days ago

Merck & Co. Earnings Preview: What to Expect

Top Stock Reports for Apple, Eli Lilly & Visa
MRK

Zacks

12 days ago

Top Stock Reports for Apple, Eli Lilly & Visa

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
MRK

StockStory

12 days ago

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

Moderna (MRNA) Stock Trades Up, Here Is Why
MRK

StockStory

12 days ago

Moderna (MRNA) Stock Trades Up, Here Is Why

How Keytruda’s Subcutaneous FDA Approval and Extended Patent Could Shape Merck’s (MRK) Investment Trajectory
MRK

Simply Wall St.

12 days ago

How Keytruda’s Subcutaneous FDA Approval and Extended Patent Could Shape Merck’s (MRK) Investment Trajectory

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
MRK

Zacks

12 days ago

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

Here's Why Merck (MRK) is a Strong Momentum Stock
MRK

Zacks

12 days ago

Here's Why Merck (MRK) is a Strong Momentum Stock

Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre
MRK

Insider Monkey

12 days ago

Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre

MRK

MT Newswires

12 days ago

Immutep Completes Dosage Optimization Requirements for Potential Lung Cancer Immunotherapy

Merck Initiates Three New Phase 2b Trials for Investigational Inflammatory Drug Tulisokibart
MRK

Insider Monkey

12 days ago

Merck Initiates Three New Phase 2b Trials for Investigational Inflammatory Drug Tulisokibart

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
MRK

Zacks

15 days ago

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

MRK

MT Newswires

15 days ago

Goldman Sachs Adjusts Merck Price Target to $93 From $94, Maintains Buy Rating

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
MRK

GlobeNewswire

16 days ago

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
MRK

Business Wire

16 days ago

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
MRK

Business Wire

16 days ago

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab
MRK

GlobeNewswire

16 days ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend
MRK

Insider Monkey

17 days ago

Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend

MRK

MT Newswires

17 days ago

Jefferies Adjusts Price Target on Merck to $137 From $141

Chart Expert Says Merck (MRK) Has More Upside – Here’s Why
MRK

Insider Monkey

17 days ago

Chart Expert Says Merck (MRK) Has More Upside – Here’s Why

Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
MRK

Zacks

17 days ago

Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings

How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
MRK

Investor's Business Daily

18 days ago

How Arcus Biosciences Aims To Take On Merck In Cancer Treatment

Energy Robotics Secures $13.5 Million Series A to Scale Critical Infrastructure Inspections with AI + Robotics
MRK

CNW Group

18 days ago

Energy Robotics Secures $13.5 Million Series A to Scale Critical Infrastructure Inspections with AI + Robotics

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK

Zacks

18 days ago

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

Top Dividend Stocks Featuring Artisan Partners Asset Management
MRK

Simply Wall St.

18 days ago

Top Dividend Stocks Featuring Artisan Partners Asset Management

MRK

MT Newswires

18 days ago

Merck Completes $10 Billion Acquisition of Verona Pharma

Merck Completes Acquisition of Verona Pharma
MRK

Business Wire

18 days ago

Merck Completes Acquisition of Verona Pharma

Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer
MRK

LA Times

18 days ago

Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer

MRK

MT Newswires

19 days ago

Verona Pharma Gets UK Court Approval for $10 Billion Sale to Merck

Assessing Merck Shares After Research Center Cuts and 13.5% Weekly Price Surge
MRK

Simply Wall St.

19 days ago

Assessing Merck Shares After Research Center Cuts and 13.5% Weekly Price Surge

MRK

MT Newswires

19 days ago

Merck Launches Three Phase 2 Trials for Tulisokibart in Inflammatory Diseases

Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
MRK

Business Wire

19 days ago

Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases

Bernstein Maintains a Hold Rating on Merck & Co (MRK)
MRK

Insider Monkey

20 days ago

Bernstein Maintains a Hold Rating on Merck & Co (MRK)

Jim Cramer on Danaher: “It Has Been a Huge Disappointment”
MRK

Insider Monkey

21 days ago

Jim Cramer on Danaher: “It Has Been a Huge Disappointment”

MRK

MT Newswires

22 days ago

US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal

5 Large Cap Drug Stocks: Values or Traps?
MRK

Zacks

22 days ago

5 Large Cap Drug Stocks: Values or Traps?

MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
MRK

Zacks

22 days ago

MRK Stock Up Nearly 14% So Far This Week: What's Driving It?

What Does Wall Street Think About Merck & Co. (MRK)?
MRK

Insider Monkey

22 days ago

What Does Wall Street Think About Merck & Co. (MRK)?

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
MRK

Motley Fool

23 days ago

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
MRK

Zacks

23 days ago

Can Novo Nordisk's Restructuring Program Drive its Return to Growth?

Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
MRK

Zacks

23 days ago

Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?

LEXX: Biodistribution Study Results
MRK

Zacks Small Cap Research

23 days ago

LEXX: Biodistribution Study Results

Merck Manuals Shares What Patients Need to Know About COPD
MRK

PR Newswire

23 days ago

Merck Manuals Shares What Patients Need to Know About COPD

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
MRK

Zacks

23 days ago

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
MRK

Zacks

23 days ago

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?

MRK

MT Newswires

23 days ago

Kinaxis to Deploy Maestro Platform for Sweden's Sobi to Boost Rare Disease Supply Chains

HEALTH CANADA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health
MRK

CNW Group

23 days ago

HEALTH CANADA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?
MRK

Pharma Voice

23 days ago

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

Share on Social Networks: